The DOI matches its Crossref record.
Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy
Abstract
BACKGROUND: Many patients with affective illness show partial or otherwise unsatisfactory responses to standard treatments, encouraging trials of combinations of pharmacologically dissimilar antidepressants. METHOD: Records of consecutive outpatients with affective disorders only partially responsive to treatment with a serotonin reuptake inhibitor (SRI) or bupropion, alone, were reviewed for changes in specific symptoms and risks of adverse events when an SRI and bupropion were combined. RESULTS: Greater symptomatic improvement was found in 19 (70%) of 27 subjects during a mean +/- SD of 11 +/- 14 months of combined daily use of bupropion (243 +/- 99 mg) with an SRI (31 +/- 16 mg fluoxetine-equivalents) than with either agent alone. Adverse effect risks were similar to those associated with each monotherapy, with a > 10% incidence of sexual dysfunction (N = 11, 41%), insomnia (N = 6, 22%), anergy (N = 4, 15%), and tremor (N = 3, 11%) during combined therapy; there were no seizures. CONCLUSION: With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Particularly relevant in the present context are previous reports [290,296,297] that although both DA and non-DA agents can be used to effectively treat mood disorders, DA agents generally have superior effects on symptoms of anhedonia, specifically when compared with non-DA agents [19,298-300].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [298]
Citations
Cited by
Sorted by citations
Items 101–160 of 160
Bupropion-associated movement disorders: A systematic review
Rissardo, J. P., & Caprara, A. L. F. (2020) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_35_19 · Cited by 12
Drug Interaction Study between Bupropion and Ticlopidine in Male CF-1 Mice
Molnari, J. C., Hassan, H. E., Moeller, B., & Myers, A. L. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.447 · Cited by 11
Management of major depressive disorder following failure of first antidepressant treatment
Shelton, R. C. (2006) · Primary psychiatry · Cited by 11
Monoaminergic‐based Pharmacotherapy for Depression
Papakostas, G. I., & D, M. F. M. (2005) · Wiley eBooks · doi:10.1002/9783527619672.ch6 · Cited by 11
Selegiline and Other Atypical Monoamine Oxidase Inhibitors in Depression
Bodkin, J. A., & Kwon, A. (2001) · Psychiatric Annals · doi:10.3928/0048-5713-20010601-08 · Cited by 10
Self-citationRestoration of positive mood states in major depression as a potential drug development target
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114532857 · Cited by 9
Treatment-Refractory Depression
Trivedi, M. H., Bettinger, T. L., & Kleiber, B. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18500-7_16 · Cited by 9
Update on augmentation of antidepressant response in resistant depression
DeBattista, C., & Lembke, A. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0064-x · Cited by 9
Bupropion-Amantadine_Associated Neurotoxicity
Trappler, B., & Miyashiro, A. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0114b · Cited by 9
Clinical Efficacy of Citalopram Alone or Augmented with Bupropion in Methadone-Stabilized Patients
Poling, J. C., Pruzinsky, R., Kosten, T. R., Gonsai, K., Sofuoglu, M., Gonzalez, G. M., & Oliveto, A. H. (2007) · American Journal on Addictions · doi:10.1080/10550490701375640 · Cited by 8
Combination Treatment With Venlafaxine and Bupropion
Kirsch, M. A., & Louie, A. K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.494 · Cited by 7
Sex and Serotonin Reuptake Inhibitor Antidepressants
Labbate, L. A. (1999) · Psychiatric Annals · doi:10.3928/0048-5713-19991001-07 · Cited by 7
Bould, H., Wiles, N., Potokar, J. P., Cowen, P. J., Nutt, D., Peters, T. J., & Lewis, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431753 · Cited by 6
Clozapine in the Treatment of Hypomania With Neurosyphilis
Mahendran, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0612e · Cited by 6
Barman, R., Kumar, S., Pagadala, B., & Detweiler, M. B. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000729 · Cited by 6
Treatment-Resistant Depression: Strategies for Management
Ruelaz, A. R. (2006) · Cited by 5
Polypharmazie in der Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_1 · Cited by 5
Schalet, B. D., Tang, T. Z., DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., & Shelton, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159647 · Cited by 4
Tratamiento farmacológico de las depresiones resistentes
Martínez, L. G. (2002) · Revista de la Asociación Española de Neuropsiquiatría · doi:10.4321/s0211-57352002000200004 · Cited by 4
Chemistry and pharmacology of novel antidepressants
Andrews, J. S., & Pinder, R. M. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8344-3_9 · Cited by 4
Clozapine Versus Chlorpromazine in Geriatric Patients
Honigfeld, G. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0114e · Cited by 4
Depression: An Update for the Clinician
Nierenberg, A. A., Eidelman, P., Wu, Y. P., & Joseph, M. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.3 · Cited by 3
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · doi:10.3109/9781420084887-5 · Cited by 3
Hagerty, B. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0612g · Cited by 2
Dr. Nafziger and Colleagues Reply
Nafziger, A. N., Bertino, J., Goss-Bley, A. I., & Kashuba, A. D. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0114d · Cited by 2
Sexual Dysfunction on Fluvoxamine Therapy
Laird, L. K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0114c · Cited by 2
Acronyms for Substance Use Disorders
Bogenschutz, M. P., & Quinn, D. K. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0612b · Cited by 2
Antidepressant treatment of juvenile depression
Bostic, J. Q., Wilens, T. E., Spencer, T., & Biederman, J. (1999) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651509909022730 · Cited by 2
Bee, R., Ahmad, M., Verma, S. K., Khan, M. I., Budruddeen, Akhtar, J., & Patel, M. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822293380240516114111 · Cited by 1
Disfunción sexual asociada a antidepresivos
Urbina, S. P. V., & Diep, R. S. (2012) · Psiquis - Hospital Psiquiátrico Fray Bernardino Alvarez · Cited by 1
A Comprehensive Review of the Evaluation, Diagnosis, and Treatment of Older Adult Bipolar Disorder
Patrick, R. E., Heintz, H., Skurla, M. D., & Forester, B. P. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00232-w · Cited by 1
Medical Management of Obesity Associated with Mood Disorders
McElroy, S. L., Kotwal, R., & Keck, P. E. (2006) · CRC Press eBooks · doi:10.3109/9780849374517.016 · Cited by 1
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · Medical psychiatry · doi:10.3109/9781420084887.003 · Cited by 1
Chapter 9. Augmentation Strategies for Treatment-Resistant Disorders
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd09 · Cited by 1
Augmentation Strategies for Treatment-Resistant Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as09 · Cited by 1
Novel Treatments for Major Depressive Disorder
Lydiard, R. B. (2009) · CNS Spectrums · doi:10.1017/s1092852900003588 · Cited by 1
Emerging Treatment Options in Treatment-Resistant Depression and Anxiety Disorders
IsHak, W. W., Rapaport, M. H., & Gotto, J. G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028935 · Cited by 1
Treadway, M. T. (2012) · Cited by 1
The Pharmacological Management of Fatigue and Sleepiness in Affective Disorders
Doghramji, K. (2006) · Springer eBooks · doi:10.1007/0-387-27682-3_20
Effects of tryptophan manipulation on neuropsychological performance
Kaploun, K. A. (2011) · Scholarship at UWindsor (University of Windsor)
Khoza, S. (2011) · Texas ScholarWorks (Texas Digital Library)
Strategies for Treatment Refractory Depression
Gören, J. L. (2001) · Journal of Pharmacy Practice · doi:10.1177/089719001129040973
Kombination von Antidepressiva
Dreimüller, N., Lieb, K., & Tadić, A. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1628630
Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_1
The Sexual Side Effects of Serotonergic Antidepressant Medications
Levine, S. B. (1998) · Springer eBooks · doi:10.1007/978-1-4899-1942-7_9
Pharmacological Approaches to Treatment-Resistant Depression
D, M. F. M., & Nierenberg, A. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50046-9
Psychopharmacology of mood disorders
Coryell, W. H., & Geddes, J. R. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.029
Schmid, S. P. (2005) · Europe PMC (PubMed Central)
García–Parés, G., Pérez‐Blanco, J., Sánchez-Pérez, M., Roncero, C., Foras, F., Gálvez, V., Cardoner, N., Crespo-Blanco, J. M., & Navarro-Odriozola, V. (2011) · Actas Españolas de Psiquiatría
Mavrogiorgou, P., & Juckel, G. (2005) · Springer eBooks · doi:10.1007/3-540-28049-9_17
Polypharmazie in der Behandlung depressiver Störungen
Schmauß, M., & Messer, T. (2006) · Springer eBooks · doi:10.1007/3-211-31221-8_1
Demographic analysis & management strategies for treatment resistant depression
Thirumalaisamy, B., Cherian, L. E., Mumthas, A. H., Murshid, C. P., Jamal, J., Anandhi, B., Rasheed, A. R. A., Balan, P., & Karthikeyan, M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.5270
Hensley, P. L., & Nurnberg, H. G. (2005) · CRC Press eBooks · doi:10.1201/b14618-85
Augmentation Strategies for Treatment-Resistant Disorders
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as09
Davanzo, P. A. (2002) · Informa Healthcare eBooks · doi:10.1201/9780203909294.ch20
Ontiveros, J. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82568
Stevenson, K. A., Hamilton, D. V., & Clayton, A. H. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as18
Zioris, G. N., Warrings, B., Deckert, J., Walther, S., Unterecker, S., & Scherf‐Clavel, M. (2026) · Pharmacopsychiatry · doi:10.1055/a-2812-9208
Metadata
- Authors
- Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J.
- Affiliations
- Harvard University (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1997-04-15
- Volume
- 58
- Issue
- 4
- Pages
- 137-145
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1982954842
- Cited by
- 159
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 4 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 6
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k05mh047370-25)
- National Institute of Mental Health (P01MH031154, MH-31154, MH47370)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- serotonin reuptake inhibitors, bupropion, antidepressant combination therapy, antidepressant monotherapy, mood disorders, adverse drug reactions, sexual dysfunction, insomnia, anergia, tremor, seizure risk
- MeSH terms
- Adult, Aged, Ambulatory Care, Anxiety Disorders, Depressive Disorder, Drug Administration Schedule, Drug Therapy, Combination, Epilepsy, Female, Fluoxetine, Humans, Male, Middle Aged, 1-Naphthylamine, Panic Disorder, Bupropion, Fluvoxamine, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Dysthymic Disorder, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review